The FIBI technology, created by Farzad Fereidouni, PhD, when combined with AI eliminates the need for frozen sections and other labor-intensive oncology surgery practices.
Guo et al. trace immune cell dynamics in patients with hepatocellular carcinoma (HCC) receiving neoadjuvant anti-PD-1 plus lenvatinib by single-cell multi-omics technologies. Compared with anti-PD-1 monotherapy,…
The James Cancer Hospital is a leader is helping cancer patients deal with the pain that can be associated with treatment. “Our inpatient oncology rehabilitation…
Get to know mathematic oncologist Heiko Enderling, Ph.D., including how he got his start in research, what excites him the most about working at MD…
This systematic review evaluates the literature and reports the incidence, time of diagnosis, and nature of therapy-related myeloid neoplasms after peptide receptor radionuclide therapy.
Melissa Loh: Protocol paper on our multicenter UR-GOAL study / cancer, Craig Maguire, Daniel Richardson, Eric J. Huselton, Heidi D. Klepin, Jane Liesveld,
Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable…
The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.
Members of the Fox Chase Cancer Center community gathered on January 21, 2025 for the Paul J. Grotzinger, MD, Memorial Lecture.
An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.
